Nycomed's Daxas gets first approval for COPD in EU
This article was originally published in Scrip
Executive Summary
Nycomed/Merck & Co's anti-inflammatory, once-daily oral therapy Daxas (roflumilast) has been granted marketing authorisation in the EU for patients with severe chronic obstructive pulmonary disease (COPD), and is expected to be launched soon in its first European countries, Germany and the UK.